Evidence map›Paper›PMID 41942356›Full record

ArticleJournal of gastric cancer2026

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy.

Hyung-Don Kim, Hyungeun Lee, Sun Young Lee, Yuna Lee, Jaewon Hyung, Meesun Moon, Jinho Shin, Young Soo Park, Min-Hee Ryu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyung-Don KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID 0000-0001-9959-0642
Hyungeun LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sun Young LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yuna LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jaewon HyungDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Meesun MoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jinho ShinDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Young Soo ParkDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Min-Hee RyuDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. miniryu@amc.seoul.kr.ORCID 0000-0002-1033-1263

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImmune checkpoint inhibitor plus chemotherapy is the standard first-line treatment for advanced gastric cancer; however, predictive biomarkers for optimal patient selection remain unsatisfactory. This study was aimed at evaluating the predictive value of tumor mutational burden (TMB) and insertion/deletion (Indel) rate in patients with gastric cancer treated with nivolumab plus chemotherapy. MATERIALS AND

methodsThis retrospective study included 132 patients with gastric cancer treated with first-line nivolumab plus chemotherapy and 185 patients treated with chemotherapy alone, all of whom had next-generation sequencing data available. The TMB and Indel cut-offs were set at 15.63 mutations per megabase and 18.19%, respectively, as determined based on their ability to best distinguish progression-free survival (PFS) among the patients who received nivolumab plus chemotherapy.

resultsPFS was favorable for nivolumab and chemotherapy than for chemotherapy alone in both the high and low TMB groups; nevertheless, survival benefits were observed only in the high Indel group. Among the subgroups defined based on both TMB and Indel rates, the high TMB and high Indel rate subgroup showed the greatest benefit from nivolumab plus chemotherapy compared with that from chemotherapy alone. The benefit of this subgroup remained significant in patients with proficient mismatch repair (MMR) tumors, whose survival outcomes were comparable to those of patients with deficient MMR tumors. Among patients treated with nivolumab plus chemotherapy, high TMB and Indel rate were independently associated with favorable survival outcomes.

conclusionsThus, Indel rate, particularly in combination with TMB, may be a promising predictive biomarker for gastric cancer. However, further validation of their predictive value is warranted.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorINDEL MutationNivolumabStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisProgression-Free SurvivalRetrospective StudiesBiomarkers, TumorNivolumabGastric cancerImmune checkpoint inhibitorInsertion and deletionPredictive biomarkerTumor mutation burden

Identifiers

PMID41942356
PMCPMC13053823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.